ArticleMaterials today. Bio2026
Advancements in nanomaterial-based adjuvants for animal vaccines.
Article in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Increasing hydrophobicity in poly(amino acid) adjuvants elicits potent and durable anti-tumor immunityBioactive materials · 2027Article
- Livestock immunomodulators as alternatives to antimicrobials - a roadmap for the fight against drug resistance.BMC veterinary research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Designing adjuvants with immunostimulatory effects is crucial for enhancing the efficacy of various vaccines, controlling the outbreak and prevalence of animal infectious diseases. The rapid advancement of nanomaterials in recent years has opened new avenues for developing veterinary vaccine adjuvants. Adjuvants prepared from nanomaterials offer multiple advantages difficult to achieve with traditional adjuvants. This review summarizes the immunological mechanisms of nanoadjuvants, focusing on recent advances in inorganic nanomaterials, organic and polymeric nanomaterials, as well as hybrid and composite nanomaterials as potential veterinary vaccine adjuvants. It categorizes various nanomaterial adjuvants based on target species, diseases, and administration routes, and provides design recommendations, where appropriate, for the selection of appropriate adjuvant platforms tailored to specific species, pathogens, vaccine types, and delivery methods.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.